Press Releases

 Filter by Provider

The recognition underscores M bank's continued focus on digital banking innovation, as Global Finance honors the neobank for the second consecutive year.

MicroVision, Inc. (NASDAQ: MVIS), a leader in advanced perception solutions for industrial, security and defense, intelligent infrastructure, and automotive applications, today announced the much-anticipated commercial production launch of MOVIA™ Pro, shipping sensors to meet customer demand.

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) in Madrid, Spain.

Approved merchants buy Sentrix films at merchant pricing and receive customer leads at no additional charge.

As digital infrastructure continues to expand, businesses are reconsidering how they acquire and manage essential network resources.

Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy.

Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO.

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today pivotal results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Participants treated with divarasib monotherapy lived significantly longer, lowering the risk of death by 44% compared with sotorasib or adagrasib (overall survival, OS, HR 0.56, [95% CI: 0.41-0.78], p=0.0005). Median OS for divarasib is currently approximately 18 months, compared to 12 months for the control arm (see table below). No new safety findings were observed with divarasib and the most common treatment-related adverse events (TRAEs) were mainly low grade and manageable. These data were presented as a late-breaking abstract during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026. Hims describes itself as a company that “operates a health and wellness platform that connects consumers to licensed healthcare professionals.”

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Shifting from "Database" to "Living Exhibition", Building a New Landmark for the Preservation and Inheritance of Linguistic and Cultural Heritage

New York, USA, October 25, 2026 -- As Halloween approaches, AVIDLOVE is highlighting versatile fashion pieces that inspire creative seasonal styling. Guided by its brand philosophy, “Confidence is Your Stage,” the brand celebrates personal expression through contemporary designs, comfortable materials, and adaptable wardrobe options. From themed celebrations to everyday outfits, AVIDLOVE encourages fashion enthusiasts to explore new combinations and make their seasonal style uniquely their own.

Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline

The wellness brand develops easy-to-use massage and recovery products designed for real-life routines at home, at work, and on the go.

The Boxery of Lyndhurst, NY, outlines how recyclable, lighter-weight affordable mailers can help ecommerce brands reduce packaging waste and respond to growing customer expectations for sustainable shipping.

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Flotek Industries To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In York To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Innventure To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hyliion To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In XTI Aerospace To Contact Him Directly To Discuss Their Options

Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA

— Xincheng Subdistrict in Yangxin County Innovates with Its “Village Gala for the People” Civic Culture Program

In October, during the golden autumn season, visitors to Shaowo Village in the “Yimeng Good Chestnuts” demonstration area of Qingyun Town, Linshu County, Linyi, Shandong Province, will find the newly renovated and reopened Sunset Café bustling with activity. Travelers from across the city and beyond gather in small groups beneath towering chestnut trees, relaxing, admiring the scenery, and chatting.

During the golden autumn season, the White-Feather Broiler Deep Processing Industrial Park in Zhengshan Subdistrict, Linshu County, Linyi, Shandong Province, is bustling with activity, with machinery roaring and construction work in full swing. Covering a planned area of 380 mu (approximately 25.3 hectares), the park aims to establish a “1+N” industrial system centered on advanced processing and extending into related sectors such as pet food, packaging, logistics, and e-commerce. The plan includes 180,000 square meters of customized, two-story factory buildings, with tenant companies expected to move in and production to begin in the second half of the year. The project is a vivid example of Linshu County’s efforts to strengthen its food processing industry chain.

In October, as clear skies and refreshing breezes sweep across the shores of the Bohai Bay, the autumn salt harvest in Wudi County has got fully underway, with more than 200,000 mu (approximately 13,333 hectares) of salt fields across the county entering the peak autumn harvesting period. Across the vast coastal flats, vibrant colors spread across the landscape as harvesting machinery moves back and forth. Once-barren saline-alkali flats have been transformed into a vivid autumn scene of thriving industry and a bountiful harvest.

MedFire Media outlines a done-for-you, multi-platform content strategy helping board-certified plastic surgeons build sustained visibility and convert more inquiries into booked consultations and surgical procedures.

MedFire Media highlights research on lead response timing, showing how delayed replies can cost plastic surgery practices consultation bookings, and outlines practical follow-up steps alongside its content marketing system.

GERMANTOWN, Md., Oct. 25, 2026 (GLOBE NEWSWIRE) -- AirTripMaker, a growing travel platform focused on connecting travelers with convenient international air travel options, is expanding its USA and Canada to India travel network to serve passengers traveling from the United States or Canada to India’s most important metropolitan, business, technology, cultural and tourism destinations.

Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-up of 5.9 months in the first-line (1L) setting and 7.1 months in the second-line (2L) setting, confirmed and unconfirmed objective response rates (ORRs) were 75% and 67%, respectively, with an ORR of 81% observed among 1L patients with left-sided tumors. With longer follow-up, most of the previously unconfirmed objective responses were subsequently confirmed, reinforcing the consistency of the clinical activity observed across treatment settings. The updated analyses reinforce the depth and durability of responses observed in both 1L and 2L treatment settings and support the ongoing global Phase 3 development program. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2026, held in Madrid, Spain.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, given before surgery (neoadjuvant) in patients with solid tumors. The results were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Vidou.ai puts greater emphasis on planning, tool selection, and cost visibility for creators and teams evaluating video and image generation.

As the global digital asset industry moves toward greater intelligence, specialization, and international expansion, technological integration and business collaboration among trading platforms are becoming increasingly important drivers of industry development. Binance, a globally recognized digital asset exchange, has announced its acquisition of BTEXCHAIN, further expanding the application of AI-driven trading technologies and advancing the development of global digital asset services.

Amid a gentle drizzle, light and shadow dance along the banks of the Oujiang River. On October 24, the 2026 FIAP World Photographer

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence 

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comprehensive Cancer Center, in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. Xencor also reported additional follow-up data supporting selection of 400 mcg/kg as the intravenous proposed recommended Phase 3 dose and outlined plans for potential registration-enabling development by the end of 2027.

MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy plus chemotherapy.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced promising preliminary clinical data from the ongoing Phase 1 monotherapy portion of its Phase 1/2 PROSPER trial evaluating FMC-376, a KRAS G12C ON+OFF inhibitor, in patients with advanced KRAS G12C-mutant solid tumors, focused on non-small cell lung cancer (NSCLC). The findings were presented during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

The rising artist unveils a new hit on the night of the harvest full moon through MILLION CROWNS MUSIC and Rawket House Creative, with production by OZ ON THE T

Overages Rescue Help offers local service businesses a free gap analysis and 12-month marketing plan, including guidance on building mobile-optimized websites designed to convert search visitors into customer inquiries and inbound calls.

October 25, 2026 -- How Mark Lehman's Power Access Control Scaled to an $8–$10M Empire

Managing a portfolio is easier today than it has ever been. The right software can turn hours of spreadsheet work into a few clicks a day, whether what you're managing is your own retirement, a kid's college fund, or a book of clients. Working smarter instead of harder starts with the best portfolio management software.